<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658033</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2012-11</org_study_id>
    <nct_id>NCT01658033</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients</brief_title>
  <official_title>Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this phase II study is to evaluate efficacy and safety of avastin plus
      modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five
      patients will be enrolled into this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anthracyclines and taxanes are the most frequently used agents for breast cancer,both in
      adjuvant and in first-line metastatic settings.For the patients who do not respond or relapse
      early after the administration of a taxane or anthracycline regimen,it is clearly needed to
      explore new combinations and schedules of drugs.Oxaliplatin has shown very promising activity
      in MBC either in monotherapy or in combination with 5-fluorouracil(5-FU) with or without
      leucovorin (LV). Avastin is a target therapy with proven efficacy in the treatment of MBC.
      Avastin plus FOLFOX regimen showed synergetic effet and been used as the standard trial in
      metastatic colorectal cancer patients. Based on the above reason, we initiate this phase II
      study to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2
      negative metastatic breast cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>response evaluation every two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Avastin + mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin + mFOLFOX6</intervention_name>
    <description>mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；
Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w</description>
    <arm_group_label>Avastin + mFOLFOX6</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age&gt;=18years

          2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) &lt;=2 and a life
             expectancy &gt;= 12 weeks;

          3. histological-proven, HER-2 negative measurable stage IV disease;

          4. exposure to anthracyclines, taxanes either in the neoadjuvant/adjuvant or in the
             metastatic setting and had documented disease progression after the firstline or
             secondline treatment

          5. Patients previously treated with radiotherapy were eligible for the study, provided
             that measurable disease existed outside the radiation field.

          6. At least 3 weeks from the prior chemotherapy or radiotherapy. At least 2 weeks from
             the prior endocrine therapy.

        Exclusion Criteria:

          1. Patients with active infection or other serious underlying medical conditions

          2. Patients had prior treatment with 5-FU infusion and/or oxaliplatin therapy

          3. Inadequate bone marrow, liver, renal, medullary, and cardiac functions

          4. Evidence of spinal cord compression or brain metastasis

          5. History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast
             cancer

          6. Pregnant or lactating women

          7. Serious uncontrolled intercurrent infection

          8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of
             bleeding

          9. Serious non-bleeding wound, peptic ulcer or bone fracture

         10. Prior dihypopyrimidine dehydrogenase deficiency

         11. Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or
             humanlised antibodies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xichun Hu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.</citation>
    <PMID>15761078</PMID>
  </reference>
  <reference>
    <citation>Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988 Nov 15;62(10):2226-33.</citation>
    <PMID>3179937</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol. 2003 Apr;14(4):537-42.</citation>
    <PMID>12649097</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Associate director of medical oncology department</investigator_title>
  </responsible_party>
  <keyword>Metastatic Breast Cancer, Her-2 negative Breast Cancer</keyword>
  <keyword>Avastin, FOLFOX regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

